|
PAT. NO. |
Title |
| 1 |
6,002,961 |
Transdermal
protein delivery using low-frequency sonophoresis |
| 2 |
6,002,954 |
Detection
of biological molecules using boronate-based chemical amplification and
optical sensors |
| 3 |
6,002,009 |
Di-substituted
1,4-piperidine esters and amides having 5-HT4 antagonistic activity |
| 4 |
6,002,001 |
Spin
trapping pharmaceutical compositions and methods for use thereof |
| 5 |
6,001,992 |
Antisense
modulation of novel anti-apoptotic bcl-2-related proteins |
| 6 |
6,001,991 |
Antisense
oligonucleotide modulation of MDR P-glycoprotein gene expression |
| 7 |
6,001,972 |
Splicing
variant of the epstein-barr virus-induced G-protein coupled receptor |
| 8 |
6,001,971 |
Human
transcription factor |
| 9 |
6,001,970 |
Modified
human neuropeptide Y1 Receptors |
| 10 |
6,001,962 |
Modified
Fas ligands |
| 11 |
6,001,884 |
Calcium
receptor-active molecules |
| 12 |
6,001,872 |
Water
soluble transplatinum complexes with anti-cancer activity and method of
using same |
| 13 |
6,001,867 |
1-aryl-dibenzothiophenes |
| 14 |
6,001,866 |
Method
for treating and preventing inflammation and atherosclerosis |
| 15 |
6,001,863 |
Isothiazolones |
| 16 |
6,001,861 |
Use
of pramipexole in the treatment of restless legs syndrome |
| 17 |
6,001,854 |
Pharmaceutical
for treating of neurological and neuropsychiatric disorders |
| 18 |
6,001,852 |
Clioquinol
for the treatment of Alzheimer's disease |
| 19 |
6,001,851 |
HIV
protease inhibitors |
| 20 |
6,001,849 |
Furopyridine,
thienopyridine pyrrolopyridine useful in controlling chemical synaptic
transmission |
| 21 |
6,001,844 |
4-Azasteroids
for treatment of hyperandrogenic conditions |
| 22 |
6,001,839 |
Substituted
4-amino-7H-pyrrolo [2,3,-d]-pyrimidines as PTK inhibitors |
| 23 |
6,001,837 |
Methods
of treating or preventing sleep apnea |
| 24 |
6,001,836 |
Dihydropyridine
NPY antagonists: cyanoguanidine derivatives |
| 25 |
6,001,820 |
Compositions
and methods for inhibiting thrombogenesis |
| 26 |
6,001,814 |
Serine
protease inhibitors |
| 27 |
6,001,813 |
Val-pro
containing .alpha.-keto oxadiazoles as serine protease inhibitors |
| 28 |
6,001,811 |
Serine
protease inhibitors--N-substituted derivatives |
| 29 |
6,001,806 |
Interferon
stimulating protein and uses thereof |
| 30 |
6,001,805 |
Method
of enhancing wound healing by stimulating fibroblast and keratinocyte
growth in vivo, utilizing amphipathic peptides |
| 31 |
6,001,652 |
Antisense
modulation of cREL expression |
| 32 |
6,001,651 |
Antisense
modulation of LFA-3 |
| 33 |
6,001,629 |
Mitochondrial
processing peptidase subunit |
| 34 |
6,001,624 |
Mitochondrial
adenylate kinase |
| 35 |
6,001,623 |
Human
protein kinase H2LAU20 |
| 36 |
6,001,622 |
Integrin-linked
kinase and its use |
| 37 |
6,001,620 |
Human
lysophosphatidic acid acyltransferase |
| 38 |
6,001,619 |
Ubiquitin
ligases, and uses related thereto |
| 39 |
6,001,607 |
Human
growth-associated methyltransfeases |
| 40 |
6,001,606 |
Polynucleotides
encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and
polypeptides encoded thereby |
| 41 |
6,001,598 |
Two
new human DnaJ-like proteins |
| 42 |
6,001,596 |
Growth-associated
protease inhibitor heavy chain precursor |
| 43 |
6,001,593 |
Human
myosin heavy chain-like proteins |
| 44 |
6,001,583 |
Methods
for disrupting GRB-7 complexes |
| 45 |
6,001,581 |
Cation-based
bioassay using human metabotropic glutamate receptors |
| 46 |
6,001,563 |
Methods
for identifying chemosensitizers |
| 47 |
6,001,390 |
Formulations
for transdermal delivery of pergolide |
| 48 |
6,001,385 |
Use
of starch for transdermal applications |
| 49 |
6,001,368 |
Method
for inhibiting or reducing the risk of macular degeneration |
| 50 |
6,001,364 |
Hetero-polyoxime
compounds and their preparation by parallel assembly |